WO2010089616A1 - Optically active 3-[(phenylpiperazin-1-yl)alkyl]-3- alkyl-oxindole derivatives having cns activity - Google Patents
Optically active 3-[(phenylpiperazin-1-yl)alkyl]-3- alkyl-oxindole derivatives having cns activity Download PDFInfo
- Publication number
- WO2010089616A1 WO2010089616A1 PCT/HU2010/000014 HU2010000014W WO2010089616A1 WO 2010089616 A1 WO2010089616 A1 WO 2010089616A1 HU 2010000014 W HU2010000014 W HU 2010000014W WO 2010089616 A1 WO2010089616 A1 WO 2010089616A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- indol
- dihydro
- ethyl
- dichloro
- Prior art date
Links
- 230000000694 effects Effects 0.000 title description 16
- -1 phenylpiperazin-1-yl Chemical group 0.000 title description 2
- 125000000217 alkyl group Chemical group 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 22
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 17
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- NOWFIMHNXPZVSK-UHFFFAOYSA-N egis-12,233 Chemical compound O=C1NC(C(=CC(Cl)=C2)Cl)=C2C1(CC)CCCCN(CC1)CCN1C1=CC=C(Cl)C=C1 NOWFIMHNXPZVSK-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 18
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 10
- 208000019901 Anxiety disease Diseases 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 230000030833 cell death Effects 0.000 claims description 6
- 208000010877 cognitive disease Diseases 0.000 claims description 6
- 230000007423 decrease Effects 0.000 claims description 6
- 230000003340 mental effect Effects 0.000 claims description 6
- 208000008811 Agoraphobia Diseases 0.000 claims description 5
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 5
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 5
- 206010041250 Social phobia Diseases 0.000 claims description 5
- 208000009205 Tinnitus Diseases 0.000 claims description 5
- 230000036506 anxiety Effects 0.000 claims description 5
- 208000016354 hearing loss disease Diseases 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 208000012201 sexual and gender identity disease Diseases 0.000 claims description 5
- 208000015891 sexual disease Diseases 0.000 claims description 5
- 231100000886 tinnitus Toxicity 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- 206010012289 Dementia Diseases 0.000 claims description 4
- 208000013200 Stress disease Diseases 0.000 claims description 4
- 239000012752 auxiliary agent Substances 0.000 claims description 4
- 206010027175 memory impairment Diseases 0.000 claims description 4
- 208000019899 phobic disease Diseases 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 230000002490 cerebral effect Effects 0.000 claims description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims description 3
- 239000000010 aprotic solvent Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003586 protic polar solvent Substances 0.000 claims description 2
- 239000011877 solvent mixture Substances 0.000 claims description 2
- 150000003892 tartrate salts Chemical class 0.000 claims description 2
- 206010026749 Mania Diseases 0.000 claims 3
- 230000036651 mood Effects 0.000 claims 3
- NSFIAKFOCAEBER-UHFFFAOYSA-N 2,3-dihydroxy-2,3-bis(4-methylphenyl)butanedioic acid Chemical compound C1=CC(C)=CC=C1C(O)(C(O)=O)C(O)(C(O)=O)C1=CC=C(C)C=C1 NSFIAKFOCAEBER-UHFFFAOYSA-N 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 201000001716 specific phobia Diseases 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 description 35
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 102000005962 receptors Human genes 0.000 description 15
- 108020003175 receptors Proteins 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000000949 anxiolytic effect Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 230000001430 anti-depressive effect Effects 0.000 description 7
- 238000000921 elemental analysis Methods 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000002249 anxiolytic agent Substances 0.000 description 5
- 230000035622 drinking Effects 0.000 description 5
- 230000000324 neuroprotective effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000012545 Psychophysiologic disease Diseases 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 230000006978 adaptation Effects 0.000 description 4
- 239000000935 antidepressant agent Substances 0.000 description 4
- 229940005513 antidepressants Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940093499 ethyl acetate Drugs 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000001525 receptor binding assay Methods 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 238000010159 Duncan test Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 description 2
- 206010020852 Hypertonia Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000538 analytical sample Substances 0.000 description 2
- 229940005530 anxiolytics Drugs 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- WBLIXGSTEMXDSM-UHFFFAOYSA-N chloromethane Chemical compound Cl[CH2] WBLIXGSTEMXDSM-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960004132 diethyl ether Drugs 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000029364 generalized anxiety disease Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- IPHNYSQCMZUVDY-UHFFFAOYSA-N 3-ethyl-1,3-dihydroindol-2-one Chemical compound C1=CC=C2C(CC)C(=O)NC2=C1 IPHNYSQCMZUVDY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 238000011785 NMRI mouse Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000035755 Psychosomatic disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000338 anxiogenic effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 150000005625 indol-2-ones Chemical class 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003923 mental ability Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000005623 oxindoles Chemical class 0.000 description 1
- 125000004095 oxindolyl group Chemical group N1(C(CC2=CC=CC=C12)=O)* 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 235000019624 protein content Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to the enantiomers of 5,7-dichloro-3- ⁇ 4-[4-(4- chlorophenyl)-piperazin- 1 -yl]butyl ⁇ -3 -ethyl- 1 ,3-dihydro-2H-indol-2-one of the Formula (II)
- the presently established therapeutic procedures used in the treatment of the above-mentioned disorders involve the administration of medicaments to the patient.
- One type of the active ingredients used in said medicaments exert their effect by acting through the benzodiazepine system (e.g. diazepam).
- Other types of active ingredients useful for the treatment or prevention of mental or psychosomatic disorders are effective by influencing the central serotonin 5-HTi A receptors (e.g. buspiron).
- the anxiolytic therapy is often supplemented with an antihypertensive (drugs acting through the ⁇ i or ⁇ 2 receptors) or an antiulcer (e.g. H 2 receptor antagonist) active ingredient.
- Benzodiazepine-type anxiolytics exhibit several undesirable side effects, including sedation, reduction of concentration, decrease in muscular tension. Such undesirable side effects significantly limit the application area of said drugs and can result in significant negative impact on the life quality of the patient.
- a further disadvantage of anxiolytics effective through the serotonin system resides in the fact that said drugs become clinically effective only after a ten to fourteen-day period of administration. It has been furthermore observed that said drugs exhibit anxiogenic (i.e. anxiety- inducing) effect in the very first period of administration. Said side effects render the cooperation of the patient and the physician difficult, since initially patients percieve that deterioration in their condition is due to the administration of the medicine.
- the present invention is based on the surprising recognition that the enantiomers of the Formula (I) differ significantly from each other and the racemic compound of the Formula (II) with regard to their pharmacological effects and receptor-binding profile.
- mixtures of the enantiomers of the Formula (I) comprising the individual enantiomers in arbitrary ratio and the mixtures of the pharmaceutically acceptable salts of the enantiomers of the Formula (I).
- a process for the preparation of the enantiomers of the Formula (I) and salts thereof As starting compound of the process, racemic 5,7-dichloro-3- ⁇ 4-[4- (4-chlorophenyl)-piperazin- 1 -yljbutyl ⁇ -3-ethyl- 1 ,3-dihydro-2H-indol-2-one of the Formula (II) is used. Said compound can be prepared according to the disclosure of International Patent Application No. WO 2005/109987.
- Enantiomers of the Formula (I) can be prepared from the racemate of the Formula (II) by resolving the racemate with an optically active acid.
- an optically active acid Surprisingly, we have found that although there are no known processes according to the state of the art which could be used for oxindole derivatives wherein the basic nitrogen atom is separated by four carbon atoms from the oxindole group, the enantiomers of the starting compound of the Formula (II) can be resolved in good yield, despite of the fact that the distance of the chiral center and the basic nitrogen atom is much greater than that in the resolving processes known from the prior art. The resolution is carried out in a dipolar aprotic or protic solvent in the presence of an optically active acid.
- an alkanol comprising 1 to 4 carbon atoms, water or mixtures thereof, preferably the mixture of ethanol and water
- an optically active tartaric acid derivative advantageously optically active dibenzoyl-tartartic acid or optically active ditoluyl-tartaric acid can be used.
- the compounds of the Formula (I) thus obtained can thereafter be converted into a pharmaceutically acceptable acid addition salt or the base can be set free from an acid addition salt.
- the pharmacological activity of the compounds of the Formula (I) according to the present invention has been tested in receptor-binding assays, Vogel's drinking conflict model in rats, Porsolt's test in mice and permanent focal cerebral ischemia model in mice.
- the basic information with regard the receptor-binding assay is disclosed in Table 1.
- the binding assays were carried out according to the method of Leysen (Leysen J. E, Niemegeers C. J. E, Van Nueten J. M., Laduron P. M.: [3H] Ketanserin (R41468), a selective [3H] ligand for Serotonine2 receptor binding. MoI Pharmacol, 21 : 301-314 (1981)).
- the tested compound was deemed to be effective in the case when the Kj value was smaller than 100 nM.
- Table 2 The results are summarized in Table 2.
- MED minimum dose resulting in statistically significant effect
- the antidepressant effect of the compounds of the Formula (I) has been established in Porsolt's test in male DBA mice weighing 20 to 25 grams. The swimming experiment was carried out in cylinders of 17.7 cm height and 12 cm diameter (Porsolt, R.D.: Behavioral despair. In: Enna, S.J., Malick, J.B., and Richelson, E. (eds.): " Antidepressants: Neurochemical, Behavioral, and Clinical Prespectives.” New York: Raven Press, 1981. pp. 121-139). In each experiment, four cylinders were used simultaneously.
- the animals were treated 30 minutes before the test with the test substances or with the vehicle in the dose of 1-3-10 mg/kg i.p. Animals were allowed to stay in the cylinder for six minutes. In the first two minutes, no measurement was made since this period was considered as the adaptation period. In the following four minutes (minutes 3 to 6 of the experiment) the time spent in immobile state was determined. The immobile time was registered for each animal with a precision of one second. The average was calculated for each group and the percentage effect was calculated for each treated group with reference for the control group. The statistical significance of the differences between groups was analyzed by Duncan-test followed by one-way variance analysis.
- MED minimum effective dose
- mice weighing 30 to 35 grams were anesthetized with 2,2,2- tribromoethanol administered intraperitoneally in the dose of 500 mg/kg (20 ml/kg).
- surgery was performed according to the surgical protocol of Welsh and coworkers (Welsh, F. A., Sakamoto, T., McKee, A., Sims, R. E.: Effect of lactacidosis on pyridine nucleotide stability during ischemia in mouse. J. Neurochem. 49: 846-851 (1987)).
- the distal part of the middle carotid artery (MCA) was occluded with electric cauter.
- Test compounds were administered intraperitoneally 30 minutes after surgery in the dose of 0.1-0.3-1.0-3.0-10.0 mg/kg). After 48 hours, mice were anesthetised by 120 mg/kg sodium pentobarbital intraperitoneally. The brains were perfused through the left ventricle with 2 ml of 4 % 2,3,5- triphenyl-tetrazolium-chloride (TTC) solution. After one hour, the brains was removed and placed into ice-cool saline for one to two minutes. Subsequently the brains were placed into 8 % aqueous formaldehyde solution. After 24 hours, the area of white lesions was determined by a computerized image analysis software. The statistical evaluation was performed by variance analysis followed by Duncan-test. Results thus obtained are demonstrated in Table 3.
- TTC 2,3,5- triphenyl-tetrazolium-chloride
- Racemic 5,7-dichloro-3- ⁇ 4-[4-(4-chlorophenyl)- piperazin-l-yl]butyl ⁇ -3-ethyl-l,3-dihydro-2H-indol-2-one of the Formula (II) exhibited significant anxiolytic, antidepressant and neuroprotective effect.
- the (+)-enantiomer of the Formula (I) showed anxiolytic acitivity only while being ineffective in the animal models suitable for the prediction of antidepressant potential and neuroprotective effect.
- the (-)-enantiomer of the Formula (I) exhibited exclusively neuroprotective effect.
- medicaments which comprise an enantiomer of the Formula (I) or a mixture thereof or pharmaceutically acceptable salt thereof alone or in admixture with one or more vehicles or auxiliary agents known from the prior art.
- the medicament according to the present invention contains the active ingredient usually in the concentration of 0.1-95 percent by weight, preferable in the concentration of 1 to 50 percent by weight, the most preferably, in the concentration of 5 to 30 percent by weight.
- Medicaments according to the present invention can be administered orally (e.g. powders, tablets, coated tablets, capsules, microcapsules, dragees, solutions, suspensions or emulsions), parenterally (e.g. in the form of intravenous, intramuscular, subcutaneous or intraperitoneal injections or in the form of an infusion), rectally (e.g. in the form of suppositories), transdermally (e.g. in the form of patches), as implants or locally (e.g. as creams, ointments or patches).
- Solid, semisolid and liquid medicaments according to the present invention can be prepared according to the processes known per se from the state of the art.
- Solid medicaments suitable for oral administration containing a compound of the Formula (I) or a pharmaceutically acceptable salt thereof as pharmaceutically active ingredient can contain vehicles, filling agents (e.g. lactose, glucose, starch, calcium phosphate, microcrystalline cellulose), binding agents (e.g. gelatin, sorbitol, polyvinylpyrrollydone), disintegrants (e.g. croscarmellose, sodium carboxymethyl-cellulose, crospovidone), tabletting aids (e.g. magnesium stearate, talc, polyethyleneglycol, silicic acid, silicon dioxide) or surfactants (e.g. sodium lauryl sulphate).
- filling agents e.g. lactose, glucose, starch, calcium phosphate, microcrystalline cellulose
- binding agents e.g. gelatin, sorbitol, polyvinylpyrrollydone
- disintegrants e.g. croscarmellose, sodium carboxymethyl-cellulose, crospovidone
- Liquid medicaments intended for oral administration containing a compound of the Formula (I) or a pharmaceutically acceptable salt thereof as active ingredient can be presented in the form of e.g. solutions, suspensions or emulsions and can contain suspending agents (e.g. gelatin, carboxymethyl cellulose), emulsifying agents (e.g. sorbitan monooleate), solvents (e.g. water, oils, glycerol, propylene glycol, ethanol), pH adjusting agents (e.g. acetate, phosphate, citrate buffers) or stabilizing agents (e.g. methyl-4-hydroxy-benzoate).
- suspending agents e.g. gelatin, carboxymethyl cellulose
- emulsifying agents e.g. sorbitan monooleate
- solvents e.g. water, oils, glycerol, propylene glycol, ethanol
- pH adjusting agents e.g. acetate, phosphate, citrate buffers
- stabilizing agents
- Liquid medicaments containing a compound of the Formula (I) or a pharmaceutically acceptable salt thereof suitable for parenteral administration are sterile isotonic solutions, which contain a pH-adjusting agent and a stabilizing agent besides the solvent.
- Semisolid medicaments containing a compound of the Formula (I) or a pharmaceutically acceptable salt thereof as active ingredient e.g. suppositories, contain the active ingredient of the Formula (I) homogeneously dispersed in the base of the suppository (e.g. in polyethylene glycol or cocoa butter).
- the use of the compounds of the Formula (I) and pharmaceutically acceptable acid addition salts thereof for the preparation of a medicament suitable for the treatment or prevention of the diseases of the central nervous system including psychosomatic disorder, anxiety, generalized anxiety disorder, panic disorder, compulsive disorder, social phobia, agoraphobia, phobias occuring in specific situations, posttraumatic stress disorder, memory disturbance following traumas, cognitive disorder, sexual disorder originating from the central nervous system origin, depression, schizofrenia, kidney insufficiency, loss of hearing, tinnitus, gastrointestinal disorders and cardiovascular diseases.
- Medicaments containing a compound of the Formula (I) or a pharmaceutically acceptable salt thereof as active ingredient can be produced by the methods of pharmaceutical technology known from the state of the art.
- the active ingredient is admixed with solid or liquid vehicles or auxiliary agents and is converted into a pharmaceutical dosage form.
- Vehicles and auxiliary agents and the processes suitable for the manufacture of the medicament are known from the art (Remington's Pharmaceutical Sciences, Edition 18, Mack Publishing Co., Easton, USA, 1990).
- Medicaments according to the present invention containing a compound of the Formula (I) or a pharmaceutically acceptable salt thereof as active ingredient contain the active ingredient in the form of dosage units.
- the daily dose of a compound of the Formula (I) or a pharmaceutically acceptable salt thereof is 0.1-1000 mg/kg body weight for adults.
- the daily dose can be administered in one or more portion.
- the actual dose depends on several factors and the prescription of the dose is the responsibility of a physician.
- the use of the compounds of the Formula (I) or a mixture thereof or a pharmaceutically acceptable salt thereof for the treatment or prevention of the diseases of the central nervous system including psychosomatic disorders, anxiety disorders, generalized anxiety disorder, panic disorder, compulsive disorder, social phobia, agoraphobia, phobias related to specific situations, stress disorder, posttraumatic stress disorder, posttraumatic cognitive disorder, cognitive disorder, sexual disorder originating from the central nervous system, kidney insufficiency, loss of hearing, depression, schizofrenia, mental decline due to cerebral cell death, Alzheimer-disease, stroke, dementia, gastrointestinal disorders or cardiovascular disorders including hypertonia, damage of the hearing organ due to pharmacotherapy or tinnitus.
- the diseases of the central nervous system including psychosomatic disorders, anxiety disorders, generalized anxiety disorder, panic disorder, compulsive disorder, social phobia, agoraphobia, phobias related to specific situations, stress disorder, posttraumatic stress disorder, posttraumatic cognitive disorder, cognitive disorder, sexual disorder originating from the central nervous system, kidney insufficiency
- the reaction mixture is stirred at room temperature for three hours and 20 ml of ethanol are added dropvise.
- the solvent is evaporated, the residue is extracted with water and ethylacetate and the organic phase is dried over sodium sulphate.
- the solvent is evaporated and the thus obtained oil is crystallized by triturating with hexane.
- the off-while crystals are stirred in 200 ml of hexane.
- the suspension is filtered, washed with hexane and dried under an infrared lamp.
- the thus obtained product can be used without recrystallization in the subsequent reactions.
- An analytical sample can be obtained by recrystallization from the mixture of hexane-ethylacetate.
- the thus obtained diastereomeric salt is added in portions into the stirred solution of 1.4 ml of concentrated ammonia solution in 15 ml of distilled water and subsequently the white suspension is stirred for two hours. The mixture is filtered, washed three times with 3 ml of water each and dried.
- Example 4 The process described in Example 4 is carried out.
- the filtrate of the first filtration is evaporated until no ethanol is present in the mixture and thereafter 3 ml of concentrated ammonia solution are added.
- the suspension is stirred until the precipitate becomes powder-like, filtered, washed three times with 5 ml of distilled water each and dried. Yield, 3.55 g (7.38 mmol), white powder.
- the base thus obtained is dissolved in 53 ml of ethanol and subsequently 2.99 g (7.75 mmol) of fS. ⁇ -di-p-toluyl-tartaric acid and 21 ml of distilled water are added. After stirring for two hours, the precipitated solids are filtered, washed three times each with 7.5 ml of ethanol- water 5:2 (v/v) solvent mixture and dried.
- the precipitated diastereomeric salt is added in portions into the solution of
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
The present invention relates to the enantiomers of 5,7-dichloro-3-{4-[4-(4- chlorophenyl)-piperazin-1-yl]butyl} -3-ethyl- 1,3-dihydro-2H-indol-2-one of the Formula (II) pharmaceutically acceptable salts thereof, process for the preparation thereof, medicinal products containing said enantiomers and the use thereof and their pharmaceutically acceptable salts in the treatment of the disorders of the central nervous system.
Description
OPTICALLY ACTIVE 3-[(PHENYLPIPERAZIN-I-YL)ALKYL]-S-
ALKYL-OXINDOLE DERIVATIVES HAVING CNS ACTIVITY
Technical field of the invention
The present invention relates to the enantiomers of 5,7-dichloro-3-{4-[4-(4- chlorophenyl)-piperazin- 1 -yl]butyl } -3 -ethyl- 1 ,3-dihydro-2H-indol-2-one of the Formula (II)
pharmaceutically acceptable salts thereof, process for the preparation thereof, medicinal products containing said enantiomers and the use thereof and their pharmaceutically acceptable salts in the treatment of the disorders of the central nervous system.
Background of the invention
From the end of the twentieth century, the civilized man is confronted with an increasing amount of information resulting from the exploding pace of technical and social development. This process results in a continous change in the adaptation pattern of man to his environment. The continously
changing enviroment renders the adjustment to the environment more and more difficult, which results in adaptation disorders. Such adaptation disorders are manifested in the form of mental or psychosomatic diseases, i.e. anxiety, stress, depression, schizofrenia, gastric ulcer, hypertonia etc.
The presently established therapeutic procedures used in the treatment of the above-mentioned disorders involve the administration of medicaments to the patient. One type of the active ingredients used in said medicaments exert their effect by acting through the benzodiazepine system (e.g. diazepam). Other types of active ingredients useful for the treatment or prevention of mental or psychosomatic disorders are effective by influencing the central serotonin 5-HTi A receptors (e.g. buspiron). When a patient is diagnosed with a psychosomatic disorder, the anxiolytic therapy is often supplemented with an antihypertensive (drugs acting through the αi or α2 receptors) or an antiulcer (e.g. H2 receptor antagonist) active ingredient.
Benzodiazepine-type anxiolytics, however, exhibit several undesirable side effects, including sedation, reduction of concentration, decrease in muscular tension. Such undesirable side effects significantly limit the application area of said drugs and can result in significant negative impact on the life quality of the patient.
A further disadvantage of anxiolytics effective through the serotonin system (i.e. buspirone, SSRIs) resides in the fact that said drugs become clinically effective only after a ten to fourteen-day period of administration. It has been furthermore observed that said drugs exhibit anxiogenic (i.e. anxiety- inducing) effect in the very first period of administration. Said side effects render the cooperation of the patient and the physician difficult, since
initially patients percieve that deterioration in their condition is due to the administration of the medicine.
Another problem of the modern society is the rapid ageing of the population. Due to the development of modern medicinal science, the life expectancy has been increasing significantly, which is closely followed by the sudden increase in the incidence of diseases appearing in old age, especially those diseases which affect mental abilities. There exists a social demand for methods and medicinal products suitable for the treatment of Alzheimer-disease, vascular dementias and senile dementia.
Furthermore, there is an increased demand for new, highly effective medicaments which can be used more effectively in the therapy than the medicinal products currently in use. The subject of the present invention is the discovery of such new, pharmaceutically active compounds.
The racemic compound 5,7-dichloro-3-{4-[4-(4-chlorophenyl)-piperazin-l- yl]butyl}-3-ethyl-l,3-dihydro-2H-indol-2-one of the Formula (II) has been disclosed for the first time in Published International Patent Application No. WO 2005/109987.
Summary of the invention
3,3-dialkyl-substituted indol-2-one derivatives disclosed in International Patent Application No. WO 2005/109987 possess significant anxiolytic activity. Said compounds bind to the 5-HT2C receptor and αj-receptors and exert dopamine release. At the same time, said compounds do not bind to the 5-HTiA receptors. This activity profile has the advantage that the above-
mentioned compounds are devoid of undesirable side effects characteristic to those compounds which bind to the 5 -HTi A receptor.
The present invention is based on the surprising recognition that the enantiomers of the Formula (I) differ significantly from each other and the racemic compound of the Formula (II) with regard to their pharmacological effects and receptor-binding profile.
Detailed description of the invention
According to the first aspect of the present invention, there is provided (+)- 5 ,7-dichloro-3 - {4-[4-(4-chlorophenyl)-piperazin- 1 -yljbutyl } -3 -ethyl- 1,3- dihydro-2H-indol-2-one of the Formula (I)
and pharmaceutically acceptable acid addition salts thereof.
According to the second aspect of the present invention, there is provided (- )-5,7-dichloro-3-{4-[4-(4-chlorophenyl)-piperazin-l-yl]-butyl}-3-ethyl-l,3- dihydro-2H-indol-2-one of the Formula (I)
and pharmaceutically acceptable salts thereof.
According to a further aspect of the present invention, there are provided the mixtures of the enantiomers of the Formula (I) comprising the individual enantiomers in arbitrary ratio and the mixtures of the pharmaceutically acceptable salts of the enantiomers of the Formula (I).
According to a further aspect of the present invention, there is provided a process for the preparation of the enantiomers of the Formula (I) and salts thereof. As starting compound of the process, racemic 5,7-dichloro-3-{4-[4- (4-chlorophenyl)-piperazin- 1 -yljbutyl } -3-ethyl- 1 ,3-dihydro-2H-indol-2-one of the Formula (II) is used. Said compound can be prepared according to the disclosure of International Patent Application No. WO 2005/109987.
Enantiomers of the Formula (I) can be prepared from the racemate of the Formula (II) by resolving the racemate with an optically active acid. Surprisingly, we have found that although there are no known processes according to the state of the art which could be used for oxindole derivatives wherein the basic nitrogen atom is separated by four carbon atoms from the oxindole group, the enantiomers of the starting compound of the Formula (II) can be resolved in good yield, despite of the fact that the distance of the chiral center and the basic nitrogen atom is much greater than that in the resolving processes known from the prior art.
The resolution is carried out in a dipolar aprotic or protic solvent in the presence of an optically active acid. As a solvent, an alkanol comprising 1 to 4 carbon atoms, water or mixtures thereof, preferably the mixture of ethanol and water can be used. As resolving acid, an optically active tartaric acid derivative, advantageously optically active dibenzoyl-tartartic acid or optically active ditoluyl-tartaric acid can be used.
The compounds of the Formula (I) thus obtained can thereafter be converted into a pharmaceutically acceptable acid addition salt or the base can be set free from an acid addition salt.
The pharmacological activity of the compounds of the Formula (I) according to the present invention has been tested in receptor-binding assays, Vogel's drinking conflict model in rats, Porsolt's test in mice and permanent focal cerebral ischemia model in mice.
In the receptor-binding assays, brain tissues from male Wistar rats weighing 120-200 g or cloned human 5-HT6 or D4 receptors were used. The protein contents of the membrane preparates were determined according to Lowry (Lowry O. H., Rosenbrough N. J., Farr A. L., Randall R. J., Protein measurement with the Folin-Phenol reagents. J Biol Chem, 193: 265-275 (1951).
The basic information with regard the receptor-binding assay is disclosed in Table 1. The binding assays were carried out according to the method of Leysen (Leysen J. E, Niemegeers C. J. E, Van Nueten J. M., Laduron P. M.: [3H]Ketanserin (R41468), a selective [3H]ligand for Serotonine2 receptor binding. MoI Pharmacol, 21 : 301-314 (1981)). The tested compound was
deemed to be effective in the case when the Kj value was smaller than 100 nM. The results are summarized in Table 2.
Table 1
*Receptor Biology Inc., Boston, USA
** BioSignal Packard Inc., Montreal, Kanada
Table 2
Table 3
MED= minimum dose resulting in statistically significant effect
The antidepressant effect of the compounds of the Formula (I) has been established in Porsolt's test in male DBA mice weighing 20 to 25 grams. The swimming experiment was carried out in cylinders of 17.7 cm height and 12 cm diameter (Porsolt, R.D.: Behavioral despair. In: Enna, S.J., Malick, J.B., and Richelson, E. (eds.): " Antidepressants: Neurochemical, Behavioral, and Clinical Prespectives." New York: Raven Press, 1981. pp. 121-139). In each experiment, four cylinders were used simultaneously. The animals were treated 30 minutes before the test with the test substances or with the vehicle in the dose of 1-3-10 mg/kg i.p. Animals were allowed to stay in the cylinder for six minutes. In the first two minutes, no measurement was made since this period was considered as the adaptation period. In the following four minutes (minutes 3 to 6 of the experiment) the time spent in immobile state was determined. The immobile time was registered for each animal with a precision of one second. The average was calculated for each group and the percentage effect was calculated for each treated group with reference for the control group. The statistical significance of the differences between groups was analyzed by Duncan-test followed by one-way variance analysis.
On the basis of the statistical significance determined for the difference of each dose from the control, MED (minimum effective dose) values were calculated. This is the smallest dose which resulted in a significant (p<0.05) effect. A significant decrease of time spent in immobility was interpreted as an antidepressant effect. The results are summarized in Table 3.
The neuroprotective effect of the compounds of the Formula (I) was tested in the permanent focal cerebral ischemia model according to the modified method of Karkoutly and coworkers (Karkoutly, C, Backhauss, C, Nuglisch, J., Krieglstein, J.: The measurement of the infarcted area after middle cerebral artery occlusion in the mouse: a screening model. In
Krieglstein, J., Oberpichler, H. ed. Pharmacology of Cerebral Ischemia 1990. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart. 63-69 (1990).).
Male NMRI mice weighing 30 to 35 grams were anesthetized with 2,2,2- tribromoethanol administered intraperitoneally in the dose of 500 mg/kg (20 ml/kg). During anesthesia, surgery was performed according to the surgical protocol of Welsh and coworkers (Welsh, F. A., Sakamoto, T., McKee, A., Sims, R. E.: Effect of lactacidosis on pyridine nucleotide stability during ischemia in mouse. J. Neurochem. 49: 846-851 (1987)). The distal part of the middle carotid artery (MCA) was occluded with electric cauter. Test compounds were administered intraperitoneally 30 minutes after surgery in the dose of 0.1-0.3-1.0-3.0-10.0 mg/kg). After 48 hours, mice were anesthetised by 120 mg/kg sodium pentobarbital intraperitoneally. The brains were perfused through the left ventricle with 2 ml of 4 % 2,3,5- triphenyl-tetrazolium-chloride (TTC) solution. After one hour, the brains was removed and placed into ice-cool saline for one to two minutes. Subsequently the brains were placed into 8 % aqueous formaldehyde solution. After 24 hours, the area of white lesions was determined by a computerized image analysis software. The statistical evaluation was performed by variance analysis followed by Duncan-test. Results thus obtained are demonstrated in Table 3.
On the basis of the tests described above, we have found that the racemic compound of the Formula (II) exhibited significant affinity towards central 5-HT6 receptors, similarly to the (+)-enantiomer of the Formula (I). However, we surprisingly found that the (-)-enantiomer of the Formula (I) was not bound to the 5-HT6 receptors. Unexpectedly, we have also found that the (+)-enantiomer of the Formula (I) did not show any significant affinity to the central 5-HT2A receptors, while at the same time, the racemic compound of the Formula (II) and the (-)-enantiomer was bound to the 5-
HT2A receptors with an affinity greater by several orders of magnitude. Furthermore, we surprisingly recognized that the three compounds exhibit significantly different affinity to the central D4 receptors. We have found that the racemic compound of the Formula (II) did not show any significant binding. In contrary, the two enantiomers of the Formula (I), especially the (-)-enantiomer have significant affinity even at lower concentration range (Table 2).
Besides the difference in the receptor binding profiles, significant difference was experienced in the predicted therapeutical application area of the three substances as well.
Significant effect suitable for prognosing the anxiolytic activity was found in the Vogel's drinking conflict test for 5,7-dichloro-3-{4-[4-(4- chlorophenyl)-piperazin-l-yl]butyl}-3-ethyl-l,3-dihydro-2H-indol-2-one of the Formula (II) after administering said compound in the dose of 5 mg/kg intraperitoneally. (+)-enantiomer of the Formula (I) showed a significant anxiolytic effect in the dose of 10 mg/kg. In contrast to the results obtained for the above-mentioned compounds, (-)-5,7-dichloro-3-{4-[4-(4- chlorophenyl)-piperazin- 1 -yl]butyl } -3 -ethyl- 1 ,3 -dihydro-2H-indol-2-one of the Formula (I) did not show any anxiolytic effect (Table 3).
A significant and unexpected difference was observed among the three compounds in the Porsolt's test in mice. Said method can be used for the prediction of antidepressant effect. The racemic compound of the Formula (II) exhibited a significant, dose-dependent antidepressant activity, while no antidepressant effect was observed for the individual enantiomers (Table 3).
With regard to the neuroprotective effect, which indicates the suitability of the test compound for the treatment of cerebral cell death, a surprising
difference was observed among the racemic 5,7-dichloro-3-{4-[4-(4- chlorophenyl)-piperazin-l-yl]butyl}-3-ethyl-l,3-dihydro-2H-indol-2-one of the Formula (II) and the two optically active isomers thereof. Cell death resulting from the occlusion of middle cerebral artery was prevented in a very low (0.1 mg/kg i.p.) dose by the racemic compound of the Formula (II). The (+)-enantiomer of the Formula (I) proved to be ineffective in this test. The (-)-enantiomer of the Formula (I) proved to be effective only in a significantly higher dose range (3 mg/kg i.p.) than the racemate (Table 3).
In summary, it was unexpectedly found that the three compounds showed surprisingly different pharmacological and consequently different therapeutical profile. Racemic 5,7-dichloro-3-{4-[4-(4-chlorophenyl)- piperazin-l-yl]butyl}-3-ethyl-l,3-dihydro-2H-indol-2-one of the Formula (II) exhibited significant anxiolytic, antidepressant and neuroprotective effect. In contrast to the above findings, the (+)-enantiomer of the Formula (I) showed anxiolytic acitivity only while being ineffective in the animal models suitable for the prediction of antidepressant potential and neuroprotective effect. The (-)-enantiomer of the Formula (I) exhibited exclusively neuroprotective effect.
According to the further aspect of the present invention, there are provided medicaments which comprise an enantiomer of the Formula (I) or a mixture thereof or pharmaceutically acceptable salt thereof alone or in admixture with one or more vehicles or auxiliary agents known from the prior art.
The medicament according to the present invention contains the active ingredient usually in the concentration of 0.1-95 percent by weight, preferable in the concentration of 1 to 50 percent by weight, the most preferably, in the concentration of 5 to 30 percent by weight.
Medicaments according to the present invention can be administered orally (e.g. powders, tablets, coated tablets, capsules, microcapsules, dragees, solutions, suspensions or emulsions), parenterally (e.g. in the form of intravenous, intramuscular, subcutaneous or intraperitoneal injections or in the form of an infusion), rectally (e.g. in the form of suppositories), transdermally (e.g. in the form of patches), as implants or locally (e.g. as creams, ointments or patches). Solid, semisolid and liquid medicaments according to the present invention can be prepared according to the processes known per se from the state of the art.
Solid medicaments suitable for oral administration containing a compound of the Formula (I) or a pharmaceutically acceptable salt thereof as pharmaceutically active ingredient can contain vehicles, filling agents (e.g. lactose, glucose, starch, calcium phosphate, microcrystalline cellulose), binding agents (e.g. gelatin, sorbitol, polyvinylpyrrollydone), disintegrants (e.g. croscarmellose, sodium carboxymethyl-cellulose, crospovidone), tabletting aids (e.g. magnesium stearate, talc, polyethyleneglycol, silicic acid, silicon dioxide) or surfactants (e.g. sodium lauryl sulphate).
Liquid medicaments intended for oral administration containing a compound of the Formula (I) or a pharmaceutically acceptable salt thereof as active ingredient can be presented in the form of e.g. solutions, suspensions or emulsions and can contain suspending agents (e.g. gelatin, carboxymethyl cellulose), emulsifying agents (e.g. sorbitan monooleate), solvents (e.g. water, oils, glycerol, propylene glycol, ethanol), pH adjusting agents (e.g. acetate, phosphate, citrate buffers) or stabilizing agents (e.g. methyl-4-hydroxy-benzoate).
Liquid medicaments containing a compound of the Formula (I) or a pharmaceutically acceptable salt thereof suitable for parenteral
administration are sterile isotonic solutions, which contain a pH-adjusting agent and a stabilizing agent besides the solvent.
Semisolid medicaments containing a compound of the Formula (I) or a pharmaceutically acceptable salt thereof as active ingredient, e.g. suppositories, contain the active ingredient of the Formula (I) homogeneously dispersed in the base of the suppository (e.g. in polyethylene glycol or cocoa butter).
According to a futher aspect of the present invention, there is provided the use of the compounds of the Formula (I) and pharmaceutically acceptable acid addition salts thereof for the preparation of a medicament suitable for the treatment or prevention of the diseases of the central nervous system including psychosomatic disorder, anxiety, generalized anxiety disorder, panic disorder, compulsive disorder, social phobia, agoraphobia, phobias occuring in specific situations, posttraumatic stress disorder, memory disturbance following traumas, cognitive disorder, sexual disorder originating from the central nervous system origin, depression, schizofrenia, kidney insufficiency, loss of hearing, tinnitus, gastrointestinal disorders and cardiovascular diseases.
Medicaments containing a compound of the Formula (I) or a pharmaceutically acceptable salt thereof as active ingredient can be produced by the methods of pharmaceutical technology known from the state of the art. The active ingredient is admixed with solid or liquid vehicles or auxiliary agents and is converted into a pharmaceutical dosage form. Vehicles and auxiliary agents and the processes suitable for the manufacture of the medicament are known from the art (Remington's Pharmaceutical Sciences, Edition 18, Mack Publishing Co., Easton, USA, 1990).
Medicaments according to the present invention containing a compound of the Formula (I) or a pharmaceutically acceptable salt thereof as active ingredient contain the active ingredient in the form of dosage units.
The daily dose of a compound of the Formula (I) or a pharmaceutically acceptable salt thereof is 0.1-1000 mg/kg body weight for adults. The daily dose can be administered in one or more portion. The actual dose depends on several factors and the prescription of the dose is the responsibility of a physician.
According to a further aspect of the present invention, there is provided the use of the compounds of the Formula (I) or a mixture thereof or a pharmaceutically acceptable salt thereof for the treatment or prevention of the diseases of the central nervous system including psychosomatic disorders, anxiety disorders, generalized anxiety disorder, panic disorder, compulsive disorder, social phobia, agoraphobia, phobias related to specific situations, stress disorder, posttraumatic stress disorder, posttraumatic cognitive disorder, cognitive disorder, sexual disorder originating from the central nervous system, kidney insufficiency, loss of hearing, depression, schizofrenia, mental decline due to cerebral cell death, Alzheimer-disease, stroke, dementia, gastrointestinal disorders or cardiovascular disorders including hypertonia, damage of the hearing organ due to pharmacotherapy or tinnitus.
The invention is demonstrated by the following examples without limiting the invention by any way.
Example 1 3-(4-chlorobutyl)-3-ethyl-l,3-dihydro-2//-indol-2-one
2.5 molar solution of «-butyl-lithium (200 ml; 0.50 mol) is weighed into a round-bottom flask which has been rinsed previously with argon. 200 ml of tetrahydrofurane are added and the solution is cooled by aceton-dry ice bath to -78 0C. At this temperature, the solution of 3-ethyl-oxindole (32.2 g; 0.20 mol) in 250 ml of tetrahydrofurane is added dropwise to the stirred reaction mixture. After ten minutes, 1-bromobutane (57.6 ml; 0.50 mol) is added dropwise and the solution is allowed to warm to room temperature. The reaction mixture is stirred at room temperature for three hours and 20 ml of ethanol are added dropvise. The solvent is evaporated, the residue is extracted with water and ethylacetate and the organic phase is dried over sodium sulphate. The solvent is evaporated and the thus obtained oil is crystallized by triturating with hexane. The off-while crystals are stirred in 200 ml of hexane. The suspension is filtered, washed with hexane and dried under an infrared lamp. The thus obtained product can be used without recrystallization in the subsequent reactions. An analytical sample can be obtained by recrystallization from the mixture of hexane-ethylacetate.
Yield, 45.8 g (91 %), white powder
Melting point, 104-105 0C (hexane-ethylacetate)
IR (KBr): 3181, 2941, 1700, 1306, 755 cm'1.
1H-NMR (CDCl3, TMS, 400 MHz): 8.57 (br s, IH, NH), 7.21 (dt, IH, J = 7.6, 1.5 Hz, H-6), 7.12 (d, IH, J = 7.4 Hz, H-4), 7.06 (dt, IH, J = 7.5, 1.0 Hz, H-5), 6.92 (d, IH, J = 7.7 Hz, H-7), 3.39 (t, 2H, J = 6.7 Hz, CH2Cl),
1.96-1.84 (m, 2H, CH2), 1.83-1.74 (m, 2H, CH2), 1.74-1.60 (m, 2H, CH2), 1.24-1.18 (m, IH), 1.08-1.03 (m, IH), 0.64 (t, 3H5 J= 7.4 Hz, CH3) ppm.
13C-NMR (CDCl3, TMS, 101 MHz): 182.4, 141.2, 132.3, 127.7, 123,0, 122.5, 109.6, 54.1, 44.4, 36.8, 32.7, 31.0, 21.8, 8.5 ppm.
Elemental analysis [calculated on the basis of the Formula Ci4Hi8ClNO
(251.76)]
Calculated: C 66.79, H 7.21, N 5.56, Cl 14.08 %.
Measured: C 66.89, H 7.16 , N 5.84, Cl 14.19 %.
Example 2 5,7-Dichloro-3-(4-chlorobutyl)-3-ethyl-l,3-dihydro-2H-indol-2-one
3-(4-chlorobutyl)-3-ethyl-l,3-dihydro-2H-indol-2-one (10.06 g; 40 mmol) are dissolved in 80 ml of glacial acetic acid and 9.6 ml (120 mmol) sulfuryl chloride is added dropwise at room temperature. Thereafter the reaction mixture is kept at 60 0C for three hours. Subsequently the reaction mixture is cooled, poured onto ice and extracted with diethylether. The ethereal layer is extracted twice with 10 percent by weight sodium hydroxide solution, dried over sodium sulphate and the solvent is evaporated. The thus obtained pale yellow oil is triturated with hexane, the white crystalline product is stirred in hexane, washed with hexane, filtered, dried and used without further purification. An analytical sample can be obtained by recrystallization from hexane.
Yield, 10.90 g (85 %) white powder
Melting point, 65-67 0C (hexane)
IR (KBr): 3165, 2964, 1713 (C=O), 1455 cm"1.
1H-NMR (CDCl3, TMS, 400 MHz): 8.38 (br s, IH, NH), 7.20 (d, IH, J = 1.9 Hz, H-6), 6.97 (d, IH, J= 1.8 Hz, H-4), 3.38 (t, 2H, J= 6.7 Hz, CH2Cl), 1.95-1.84 (m, 2H, CH2), 1.76-1.60 (m, 4H, 2 x CH2), 1.19-1.16 (m, IH), 1.04-0.96 (m, IH), 0.62 (t, 3H, J= 7.4 Hz, CH3) ppm.
13C-NMR (CDCl3, TMS, 101 MHz): 180.5, 137.7, 135.1, 128.3, 127.6, 121.9, 115.7, 55.7, 44.3, 36.8, 32.5, 31.0, 21.7, 8.5 ppm.
Elemental Analysis [calculated on the basis of the Formula Ci4Hi6Cl3NO
(320.65)]
Calculated: C 52.44, H 5.03, N 4.37, Cl 33.17 %
Measured: C 52.37, H 4.97, N 4.27, Cl 33.18 %
Example 3
5,7-DichIoro-3-{4-[4-(4-chIorophenyl)-piperazin-l-yl]butyl}-3-ethyl-l,3- dihydro-2/7-indol-2-one
l-(4-chlorophenyl)-piperazine (2.36 g; 12 mmol) is heated under slow stirring to 180 0C and at this temperature, 5,7-dichloro-3-(4-chlorobutyl)-3- ethyl-l,3-dihydro-2H-indol-2-one (3.85 g, 12 mmol) and sodium carbonate
(1.36 g; 12 mmol) are added. After one hour, the melt is allowed to cool, ethylacetate and water are added and the layers are separated. The organic phase is evaporated and the thus obtained oil is subjected to column chromatographic purification using Kieselgel 60 stationary phase and ethylacetate as eluent. The main fraction contains the oily product, which is crystallized by triturating with diethylether, filtered and recrystallized from the mixture of heptane-ethylacetate.
Yield, 3.46 g (60 %), white powder
Melting point, 152- 154 °C (heptane-ethylacetate)
IR (KBr): 3137, 1719 (C=O), 826 cm'1.
1H-NMR (CDCl3, TMS, 400 MHz): 0.65 (3H, t, J = 7.4 Hz), 0.98-0.86 (IH, m), 1.16-1.04 (IH, m), 1.50-1.36 (2H, m), 1.80-1.70 (2H, m), 1.98-1.88 (2H, m), 2.27 (2H, t, J = 7.8 Hz), 2.51 (4H, t, J = 5.0 Hz), 3.12 (4H, t, J =
5.0 Hz), 6.81 (2H, d, J = 9.1 Hz), 7.01 (IH, d, J = 1.8 Hz), 7.18 (2H, d, J =
9.1 Hz), 7.23 (IH, d, J = 1.8 Hz), 8.15 (IH, s) ppm.
13C-NMR (CDCl3, TMS, 101 MHz): 180.3, 149.9, 137.7, 135.3, 128.9, 128.2, 127.5, 124.4, 122.0, 117.1, 115.7, 57.9, 55.8, 53.0, 49.1, 37.5, 31.1, 26.7, 22.2, 8.5 ppm.
Elemental Analysis [calculated on the basis of the Formula C24H28Cl3N3O
(480.87)]
Calculated: C 59.95, H 5.87, Cl 22.12, N 8.74 %.
Measured: C 59.80, H 5.86, Cl 21.83, N 8.72 %.
Example 4
Preparation of (+)-5,7-Dichloro-3- {4-[4-(4-chlorophenyl)-piperazin-l- yl]butyl}-3-ethyl-l,3-cHhydro-2/y-indol-2-one by resolving of the racemate
5.00 g (10.40 mmol) racemic 5,7-dichloro-3-{4-[4-(4-chlorophenyl)- piperazin- 1 -yl] -butyl } -3 -ethyl- 1 ,3 -dihydro-2H-indol-2-one base are suspended in 75 ml of ethanol and 4.22 g (10.93 mmol) of f7?,/^-di-p-toluyl- tartaric acid are added in portions, while the suspension becomes gradually clear. After complete dissolution, 30 ml of water are added and the mixture is stirred for two hours. After stirring, the precipitated white substance is filtered off, washed with 10 ml portions of the solvent ethanol- water 5:2 (v/v) three times and dried.
Yield, 2.60 g (57.6 %) white powder (diastereomeric salt)
Melting point, 140-142 °C
[Ot]365 (c=l, MeOH) = +226.1°
1H-NMR (CDCl3, TMS, 500 MHz): 8.35 (s, IH), 7.89 (d, 4H, J = 8.2 Hz), 7.20 (d, IH, J = 1.8 Hz), 7.12 (d, 2H, J = 8.7 Hz), 7.10 (d, 4H, J = 8.1 Hz), 7.00 (d, IH, J = 1.8 Hz), 6.64 (d, 2H, J = 8.9 Hz), 5.80 (s, 2H), 3.19 (m, 4H), 3.04 (m, 4H), 2.72 (m, 2H), 2.34 (s, 6H), 1.87 (m, 2H), 1.70 (m, 2H), 1.59 (m, 2H), 1.01 (m, IH), 0.91 (m, IH), 0.61 (t, 3H).
Elemental Analysis [calculated on the basis of the Formula C44H46Cl3N3O9 (867.23)]:
Calculated: C 60.94, H 5.35, Cl 12.26, N 4.85 %. Measured: C 60.79, H 5.45, Cl 12.41, N 4.83 %.
The thus obtained diastereomeric salt is added in portions into the stirred solution of 1.4 ml of concentrated ammonia solution in 15 ml of distilled water and subsequently the white suspension is stirred for two hours. The mixture is filtered, washed three times with 3 ml of water each and dried.
Yield, 1.42 g (56.8 %) (+)-5,7-dichloro-3-{4-[4-(4-chlorophenyl)-piperazin- l-yl]-butyl}-3-ethyl-l,3-dihydro-2H-indol-2-one (enantiomeric purity > 99 %).
Melting point, 139-141 °C
[(X]365 (c=l, MeOH) = +8.1°
IR(KBr): 3137, 1719,826 cm"
1H-NMR (CDCl3, TMS, 400 MHz): 0.65 (3H, t, J = 7.4 Hz), 0.98-0.86 (IH, m), 1.16-1.04 (IH, m), 1.50-1.36 (2H, m), 1.80-1.70 (2H, m), 1.98-1.88 (2H, m), 2.27 (2H, X, J = 7.8 Hz), 2.51 (4H, t, J = 5.0 Hz), 3.12 (4H, t, J =
5.0 Hz), 6.81 (2H, d, J = 9.1 Hz), 7.01 (IH, d, J = 1.8 Hz), 7.18 (2H, d, J =
9.1 Hz), 7.23 (IH, d, J = 1.8 Hz), 8.15 (IH, s) ppm.
13C-NMR (CDCl3, TMS, 101 MHz): 180.3, 149.9, 137.7, 135.3, 128.9, 128.2, 127.5, 124.4, 122.0, 117.1, 115.7, 57.9, 55.8, 53.0, 49.1, 37.5, 31.1, 26.7, 22.2, 8.5 ppm.
Elemental Analysis [calculated on the basis of the Formula C24H28Cl3N3O
(480.87)]
Calculated: C 59.95, H 5.87, Cl 22.12, N 8.74 %.
Measured: C 59.89, H 5.81, Cl 22.03, N 8.92 %.
Example 5
Preparation of (-)-5,7-Dichloro-3-{4-[4-(4-chlorophenyl)-piperazin-l- yl]-butyl}-3-ethyl-l,3-dihydro-2//-indol-2-one by resolving the racemate
The process described in Example 4 is carried out. The filtrate of the first filtration is evaporated until no ethanol is present in the mixture and thereafter 3 ml of concentrated ammonia solution are added. The suspension is stirred until the precipitate becomes powder-like, filtered, washed three times with 5 ml of distilled water each and dried. Yield, 3.55 g (7.38 mmol), white powder.
The base thus obtained is dissolved in 53 ml of ethanol and subsequently 2.99 g (7.75 mmol) of fS.^-di-p-toluyl-tartaric acid and 21 ml of distilled water are added. After stirring for two hours, the precipitated solids are filtered, washed three times each with 7.5 ml of ethanol- water 5:2 (v/v) solvent mixture and dried.
Yield, 3.36 g (74.6 %) white powder (diastereomeric salt)
Melting point, 140-142 °C
[Ci]365 (c=l, MeOH) - -225.6°
1H-NMR (CDCl3, TMS, 500 MHz): 8.35 (s, IH), 7.89 (d, 4H, J = 8.2 Hz), 7.20 (d, IH, J = 1.8 Hz), 7.12 (d, 2H, J = 8.7 Hz), 7.10 (d, 4H, J = 8.1 Hz), 7.00 (d, IH, J = 1.8 Hz), 6.64 (d, 2H, J = 8.9 Hz), 5.80 (s, 2H), 3.19 (m, 4H),
3.04 (m, 4H), 2.72 (m, 2H), 2.34 (s, 6H), 1.87 (m, 2H), 1.70 (m, 2H), 1.59 (m, 2H), 1.01 (m, IH), 0.91 (m, IH), 0.61 (t, 3H).
Elemental Analysis [calculated on the basis of the Formula C44H46Cl3N3O9
(867.23)]
Calculated: C 60.94, H 5.35, Cl 12.26, N 4.85 %.
Measured: C 59.59, H 5.40, Cl 12.39, N 4.88 %.
The precipitated diastereomeric salt is added in portions into the solution of
1.5 ml concentrated ammonia solution in 15 ml of water and stirred for two hours. Subsequently the mixture is filtered, washed three times with 1.5 ml of water each and dried.
Yield, 1.83 g (73.2 %) (-)-5,7-dichloro-3-{4-[4-(4-chlorophenyl)-piperazin- l-yl]butyl}-3-ethyl-l,3-dihydro-2H-indol-2-one (enantiomer content > 99
%)
Melting point, 139-140 °C
[Ct]365 (c=l, MeOH) = -7.8°
IR (KBr): 3137, 1719 (C=O), 826 cm"
1H-NMR (CDCl3, TMS, 400 MHz): 0.65 (3H, t, J = 7.4 Hz), 0.98-0.86 (IH, m), 1.16-1.04 (IH, m), 1.50-1.36 (2H, m), 1.80-1.70 (2H, m), 1.98-1.88 (2H, m), 2.27 (2H, t, J = 7.8 Hz), 2.51 (4H, t, J = 5.0 Hz), 3.12 (4H, t, J =
5.0 Hz), 6.81 (2H, d, J = 9.1 Hz), 7.01 (IH, d, J = 1.8 Hz), 7.18 (2H, d, J =
9.1 Hz), 7.23 (IH, d, J = 1.8 Hz), 8.15 (IH, s) ppm.
13C-NMR (CDCl3, TMS, 101 MHz): 180.3, 149.9, 137.7, 135.3, 128.9, 128.2, 127.5, 124.4, 122.0, 117.1, 115.7, 57.9, 55.8, 53.0, 49.1, 37.5, 31.1, 26.7, 22.2, 8.5 ppm.
Elemental Analysis [calculated on the basis of the Formula C24H28Cl3N3O
(480.87)]
Calculated: C 59.95, H 5.87, Cl 22.12, N 8.74 %.
Measured: C 60.08, H 5.80, Cl 21.89, N 8.98 %.
Claims
1. Enantiomers of 5,7-dichloro-3-{4-[4-(4-chlorophenyl)-piperazin-l- yl]butyl}-3-ethyl-l,3-dihydro-2H-indol-2-one of the Formula (II),
2. Mixtures of the enantiomers of the Formula (I) and pharmaceutically acceptable salts thereof.
3. (+)-5,7-Dichloro-3-{4-[4-(4-chlorophenyl)-piperazin-l-yl]butyl}-3- ethyl-l,3-dihydro-2H-indol-2-one of the Formula (I)
and pharmaceutically acceptable salts thereof.
4. (-)-5,7-dichloro-3-{4-[4-(4-chlorophenyl)-piperazin-l-yl]butyl}-3- ethyl-l,3-dihydro-2//-indol-2-one of the Formula (I)
and pharmaceutically acceptable salts thereof.
5. Medicaments containing (+)-5,7-dichloro-3-{4-[4-(4-chlorophenyl)- piperazin-l-yl]butyl}-3-ethyl-l,3-dihydro-2H-indol-2-one of the Formula (I) or (-)-5,7-dichloro-3-{4-[4-(4-chlorophenyl)-piperazin- l-yl]butyl}-3-ethyl-l,3-dihydro-2H-indol-2-one of the Formula (I) or a mixture of said enantiomers of the Formula (I) or a pharmaceutically acceptable salt thereof as active ingredient.
6. Medicaments according to claim 3 suitable for the treatment or prevention of the diseases of the central nervous system including depression, anxiety, schizofrenia, mood disturbance, social phobia, agoraphobia, other specific phobias, mania, mental decline, cognitive disorder, sexual disorders of central nervous system origin, memory disturbance following trauma, posttraumatic stress disorder, cerebral trauma, dementia, cell death occuring in the central nervous system, Alzheimer-disease, stress disease, gastrointestinal diseases, cardiovascular diseases, kidney insufficiency, tinnitus and loss of hearing.
7. Process for the preparation of (+)-5,7-dichloro-3-{4-[4-(4- chlorophenyl)-piperazin- 1 -yl]buty 1 } -3 -ethyl- 1 ,3 -dihydro-2H-indol- 2-one of the Formula (I) or (-)-5,7-dichloro-3-{4-[4-(4- chlorophenyl)-piperazin- 1 -yljbutyl } -3-ethyl- 1 ,3-dihydro-2H-indol- 2-one, which comprises resolving a mixture of the (+)-enantiomer of the Formula (II) and the (-)-enantiomer of the Formula (I) with an optically active acid.
8. Process according to claim 7, characterized in that racemic 5,7- dichloro-3-{4-[4-(4-chlorophenyl)-piperazin-l-yl]butyl}-3-ethyl-l,3- dihydro-2H-indol-2-one of the Formula (II) is used as starting material.
9. Process according to claim 7 or claim 8, characterized in that as optically active acid, an optically active tartaric acid derivative, preferably optically active di-p-toluyl-tartaric acid is used.
10. Process according to any of claims 7 to 9, characterized in that the resolution of the enantiomers is carried out in a dipolar aprotic or protic solvent, preferably in the mixture of an aliphatic alcohol comprising 1 to 4 carbon atoms and water.
11. Process according to any of claims 7 to 10, characterized in that the resolution is carried out in ethanol-water solvent mixture, using optically active di-p-toluyl-tartaric acid.
12. The use of (+)- or (-)-5,7-dichloro-3-{4-[4-(4-chlorophenyl)- piperazin-l-yl]butyl}-3-ethyl-l,3-dihydro-2H-indol-2-one of the Formula (I) as medicament.
13. Process for the preparation of a medicament suitable for the treatment or prevention of diseases of the central nervous system including depression, anxiety, schizofrenia, mood disturbance, social phobia, agoraphobia, phobias resulting from specific circumstances, mania, compulsive disorder, mental decline, cerebral damage, memory disturbances following traumas, posttraumatic stress disorder, cognitive disorder, sexual disorders of central nervous system origin, dementia, cellular death occuring within the central nervous system, Alzheimer-disease, stress disorder, gastrointestinal diseases, cardiovascular diseases, kidney insufficiency, tinnitus, loss of hearing, characterized in that (+)-5,7-dichloro-3-{4-[4-(4- chlorophenyl)-piperazin- 1 -yl]butyl } -3 -ethyl- 1 ,3 -dihydro-2H-indol- 2-one of the Formula (I) or (-)-5,7-dichloro-3-{4-[4-(4- chlorophenyl)-piperazin- 1 -yl]butyl } -3 -ethyl- 1 ,3 -dihydro-2H-indol- 2-one of the Formula (I) or a mixture thereof or a pharmaceutically acceptable salt thereof is admixed with pharmaceutically acceptable vehicles or optionally with auxiliary agents and the mixture is converted into a pharmaceutical dosage form.
14. Method for the treatment or prevention of the diseases of the central nervous system including diseases of the central nervous system including depression, anxiety, schizofrenia, mood disturbance, social phobia, agoraphobia, phobias resulting from specific circumstances, mania, compulsive disorder, mental decline, cerebral damage, memory disturbances following traumas, posttraumatic stress disorder, cognitive disorder, sexual disorders of central nervous system origin, dementia, cellular death occuring within the central nervous system, Alzheimer-disease, stress disorder, gastrointestinal diseases, cardiovascular diseases, kidney insufficiency, tinnitus, loss of hearing, characterized in that a therapeutically effective amount of the (+)-5,7-dichloro-3-{4-[4-(4-chlorophenyl)-piperazin-l-yl]butyl}- 3-ethyl-l,3-dihydro-2H-indol-2-one of the Formula (I) or (-)-5,7- dichloro-3 - { 4- [4-(4-chlorophenyl)-piperazin- 1 -yl] butyl } -3 -ethyl- 1,3- dihydro-2//-indol-2-one of the Formula (I) is administered to a patient in need of such treatment.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011548788A JP2012517413A (en) | 2009-02-06 | 2010-02-05 | Optically active 3-[(phenylpiperazin-1-yl) alkyl] -3-alkyl-oxindole derivatives having central nervous system activity |
| US13/146,693 US20120108607A1 (en) | 2009-02-06 | 2010-02-05 | Optically active 3-[(phenylpiperazin-1-yl)alkyl]-3- alkyl-oxindole derivatives having cns activity |
| EP10707659.8A EP2393778B1 (en) | 2009-02-06 | 2010-02-05 | Optically active 3-[(phenylpiperazin-1-yl)alkyl]-3- alkyl-oxindole derivatives having CNS activity |
| EA201190133A EA018981B1 (en) | 2009-02-06 | 2010-02-05 | Optically active 3-[(phenylpiperazin-1-yl)alkyl]-3- alkyloxindole derivatives having cns activity |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU0900071A HUP0900071A2 (en) | 2009-02-06 | 2009-02-06 | Optically active 3-[(phenyl-piperazin-1-yl)alkyl]-3-alkyl-oxindole derivatives influencing the central nervous system and pharmaceutical compositions containing them |
| HUP0900071 | 2009-02-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2010089616A1 true WO2010089616A1 (en) | 2010-08-12 |
Family
ID=89988765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/HU2010/000014 WO2010089616A1 (en) | 2009-02-06 | 2010-02-05 | Optically active 3-[(phenylpiperazin-1-yl)alkyl]-3- alkyl-oxindole derivatives having cns activity |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20120108607A1 (en) |
| EP (1) | EP2393778B1 (en) |
| JP (1) | JP2012517413A (en) |
| EA (1) | EA018981B1 (en) |
| HU (1) | HUP0900071A2 (en) |
| WO (1) | WO2010089616A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005109987A2 (en) | 2004-05-11 | 2005-11-24 | Egis Gyógyszergyár Nyrt. | 3-(((4-phenyl)-piperazine-1-yl)-alkyl)-3-alkyl-1, 3-dihydro-2h-indol-2-one derivatives and related compounds for the treatment of central nervous system disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2635104B1 (en) * | 1988-08-03 | 1992-04-30 | Synthelabo | INDOLONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| DE4101686A1 (en) * | 1991-01-22 | 1992-07-23 | Merck Patent Gmbh | INDOLDER DERIVATIVES |
-
2009
- 2009-02-06 HU HU0900071A patent/HUP0900071A2/en unknown
-
2010
- 2010-02-05 WO PCT/HU2010/000014 patent/WO2010089616A1/en active Application Filing
- 2010-02-05 JP JP2011548788A patent/JP2012517413A/en active Pending
- 2010-02-05 EA EA201190133A patent/EA018981B1/en not_active IP Right Cessation
- 2010-02-05 EP EP10707659.8A patent/EP2393778B1/en active Active
- 2010-02-05 US US13/146,693 patent/US20120108607A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005109987A2 (en) | 2004-05-11 | 2005-11-24 | Egis Gyógyszergyár Nyrt. | 3-(((4-phenyl)-piperazine-1-yl)-alkyl)-3-alkyl-1, 3-dihydro-2h-indol-2-one derivatives and related compounds for the treatment of central nervous system disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| EA018981B1 (en) | 2013-12-30 |
| US20120108607A1 (en) | 2012-05-03 |
| EA201190133A1 (en) | 2012-02-28 |
| EP2393778A1 (en) | 2011-12-14 |
| EP2393778B1 (en) | 2014-04-09 |
| JP2012517413A (en) | 2012-08-02 |
| HUP0900071A2 (en) | 2010-10-28 |
| HU0900071D0 (en) | 2009-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CZ304702B6 (en) | (4R) and (4S) Diastereoisomers of (2S)-2-[2-oxo-4-propylpyrrolidinyl] butanamide, pharmaceutical composition containing thereof and their use | |
| MXPA05009089A (en) | Indolone-acetamide derivatives, processes for preparing them and their uses. | |
| US20090182012A1 (en) | Piperidin-2, 6-dione pamoate salts and their use for the treatment of affective disorders | |
| WO2006058993A1 (en) | Arylpiperazine derivatives and their use as ligands selective of the dopamine d3 receptor | |
| EP1776339B1 (en) | 3-(((4-phenyl)-piperazin-1-yl)-alkyl)-3-alkyl-1,3-dihydro-2h-indol-2-one derivatives and related compounds for the treatment of central nervous system disorders | |
| EP2393778B1 (en) | Optically active 3-[(phenylpiperazin-1-yl)alkyl]-3- alkyl-oxindole derivatives having CNS activity | |
| EA010154B1 (en) | Pyridine derivatives of alkyl oxindoles as 5-ht7 receptor active agents | |
| EP0629615B1 (en) | Indole derivatives as glutamate antagonists | |
| WO1998014444A1 (en) | N-(benzothiazol-2-yl) piperidine-1-ethanamine derivatives, their preparation and application in therapeutics | |
| AU2005240842B2 (en) | Piperazine derivatives of alkyl oxindoles | |
| JP2020536070A (en) | New salt | |
| JP2001512731A (en) | 1,3-Dioxolo / 4,5-H / 2,3 / benzodiazepine derivatives as AMPA / Kainate receptor inhibitors | |
| JP2000501699A (en) | 1- [2- (2,3-Dihydro-1H-inden-1-yl) ethyl] -4- (naphthalen-1-yl) piperazine Derivative, Production Method and Application to Therapeutics | |
| JPWO2006121104A1 (en) | Crystals of indole derivatives having a piperidine ring and their production | |
| MXPA98005698A (en) | Derivatives of 5h-tiazolo [3,2-a] pyramid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10707659 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2011548788 Country of ref document: JP |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2010707659 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 201190133 Country of ref document: EA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 13146693 Country of ref document: US |